Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,463 total articles

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

Eupraxia Pharmaceuticals announced that three abstracts from their ongoing Phase 1b/2 RESOLVE trial of EP-104GI, a local drug delivery treatment for eosinophilic esophagitis (EoE), will be presented at the American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) 2026 conferences. The data highlight improvements in dysph…

Rezolve Ai Opens Retail to Any AI Shopping Agent with RezolvePay, Targeting a Multi-Trillion-Dollar Commerce Opportunity

Rezolve Ai Opens Retail to Any AI Shopping Agent with RezolvePay, Targeting a Multi-Trillion-Dollar Commerce Opportunity

Rezolve Ai has introduced RezolvePay, a payment and commerce infrastructure that allows AI-driven consumer shopping agents to interact seamlessly with merchant systems and complete purchases both online and in physical stores. This new platform positions Rezolve Ai to capitalize on the emerging agentic commerce market, potentially addressing $3 to …

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in  ReVeRA-301 Phase 3 Clinical Trial

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Milestone Pharmaceuticals has enrolled its first European participant in the ReVeRA-301 Phase 3 clinical trial evaluating etripamil nasal spray for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial aims to enroll approximately 150 patients across multiple sites including the Dutch Cardiovascular Investigator Network to …

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on complement-related conditions and oncology, announced participation in the Maxim Growth Summit 2026. Senior management will present in a panel discussion focusing on immunology and inflammation therapies. The company highlighted its lead drug candidate ciprocopan recently approv…

Stride to Appoint Steven Guttentag and Dylan Haggart to Board of Directors and Form Capital Allocation Committee

Stride to Appoint Steven Guttentag and Dylan Haggart to Board of Directors and Form Capital Allocation Committee

Stride, Inc., a leading education technology company, announced the appointment of Dr. Steven Guttentag and Dylan Haggart to its Board of Directors. Alongside these appointments, Stride is forming a Capital Allocation Committee to evaluate its capital structure and priorities, aiming to maximize long-term shareholder value. The company plans to eng…

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Quince Therapeutics has rebranded as IRulya Therapeutics following a merger with Orphai Therapeutics and a significant capital raise. The company will trade on Nasdaq under the ticker IRLA, focusing on the clinical development of LAM-001, a novel inhaled formulation of rapamycin targeting mTOR pathways implicated in several severe pulmonary disease…

VCI Global Clarifies Structure of US$125 Million Standby Equity Purchase Facility, Emphasizes Flexible Capital Strategy

VCI Global Clarifies Structure of US$125 Million Standby Equity Purchase Facility, Emphasizes Flexible Capital Strategy

VCI Global Limited announced clarification on its US$125 million standby equity purchase facility with Hudson Global Ventures, highlighting that no funds have been drawn to date. The flexible facility allows VCI to access capital over 36 months, aligning with its growth strategies in AI infrastructure and renewable energy projects. The company emph…

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Profound Medical Corp. and Telix Pharmaceuticals have entered a co-education agreement to educate healthcare professionals on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO platform for prostate cancer care. The collaboration aims to increase physician awareness, facilitate better pati…

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Sagimet Biosciences announced that its license partner Ascletis demonstrated positive 52-week Phase 3 open-label extension results for denifanstat, an oral fatty acid synthase inhibitor, in treating moderate to severe acne vulgaris. The drug showed continuing efficacy and safety with significant improvements in clinical endpoints. Sagimet is now ad…

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Teva Pharmaceutical Industries Ltd. announced FDA approval of WELTRUZA™, the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for treating schizophrenia in adults. This new treatment requires no loading doses, no oral supplementation, and no post-injection monitoring. The approval was based on positive Phase…

Aurora Mobile’s JPush Strengthens Shennong Group’s Messaging Infrastructure to Support Timely Delivery of Critical Business Information

Aurora Mobile’s JPush Strengthens Shennong Group’s Messaging Infrastructure to Support Timely Delivery of Critical Business Information

Aurora Mobile Limited (NASDAQ: JG) has partnered with Yunnan Shennong Agricultural Industry Group to deploy its JPush intelligent push notification solution. This collaboration aims to improve the reliability and timeliness of critical business alerts within Shennong Group's digital agriculture value chain, addressing challenges posed by mobile app…

Wrap Appoints Veteran Law Enforcement Leader John “Chappy” Chapman as Vice President of Training and Missions

Wrap Appoints Veteran Law Enforcement Leader John “Chappy” Chapman as Vice President of Training and Missions

Wrap Technologies, a Nasdaq-listed provider of non-lethal response technologies, announced the appointment of John "Chappy" Chapman as Vice President of Training and Missions. Chapman brings over 30 years of law enforcement and tactical training expertise to lead the scaling and standardization of Wrap's non-lethal response training programs across…

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals will host a virtual Investor Day on October 29, 2026, discussing the development of mavorixafor, an oral CXCR4 antagonist in late-stage trials for treating chronic neutropenia. The event features management updates on the Phase 3 4WARD trial, plans for a Phase 2 trial combining mavorixafor with G-CSF, and presentations by hematol…

Manhattan Bridge Capital, Inc. Announces Increase and Extension of its Existing Buy-Back of up to 250,000 of its Common Shares

Manhattan Bridge Capital, Inc. Announces Increase and Extension of its Existing Buy-Back of up to 250,000 of its Common Shares

Manhattan Bridge Capital, Inc. has announced that its Board has approved increasing its common share repurchase program from 100,000 to 250,000 shares and extended the program for an additional 12 months. The company offers short-term secured loans to real estate investors in the New York metropolitan area and Florida. This buy-back initiative refl…

Barrick to Report Third Quarter 2026 Results on November 9

Barrick to Report Third Quarter 2026 Results on November 9

Barrick Mining Corporation will announce its third quarter 2026 financial results on November 9, 2026, before market open. The company will also host a live webcast and presentation followed by a Q&A session with analysts. As a major global gold and copper mining company, Barrick continues its disciplined growth and responsible mining operations ac…

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Balchem Corporation announced it will hold a conference call on October 23, 2026, to discuss its third quarter financial results. The company's leadership, including CEO Ted Harris and CFO Martin Bengtsson, will host the call. Results and financial exhibits will be published prior to the call and available on Balchem's website. The company operates…

Viomi Technology Co., Ltd Announces Board Changes

Viomi Technology Co., Ltd Announces Board Changes

Viomi Technology Co., Ltd, a leading AI-driven home water systems company listed on NASDAQ (VIOT), announced the appointment of Mr. Xinlang Yu to its board of directors, replacing Mr. Qian Sun who resigned for personal reasons. Mr. Yu brings extensive experience from Xiaomi Corporation, enhancing Viomi's expertise in smart home appliance management…

Transocean Ltd. Announces Contract Backlog of Approximately $1.1 Billion, Including Fully Approved Equinor Agreement

Transocean Ltd. Announces Contract Backlog of Approximately $1.1 Billion, Including Fully Approved Equinor Agreement

Transocean Ltd. announced a significant increase in its firm contract backlog to around $1.1 billion following the formal approval of a previously announced Equinor agreement worth $1.0 billion and a new two-well contract with A/S Norske Shell valued at approximately $62 million. The contracts involve offshore drilling operations primarily in Norwa…